Psychosomatics
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Psychosomatics 48:405-411, October 2007
doi: 10.1176/appi.psy.48.5.405
© 2007 Academy of Psychosomatic Medicine
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Freudenreich, O.
* Articles by Goff, D. C.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Freudenreich, O.
* Articles by Goff, D. C.
Related Collections
* Schizophrenia Spectrum Disorders
* Syndromes Secondary to General Medical Disorders

Hepatitis C in Schizophrenia: Screening Experience in a Community-Dwelling Clozapine Cohort

Oliver Freudenreich, M.D., Rajesh T. Gandhi, M.D, Jared P. Walsh, B.A., David C. Henderson, M.D., and Donald C. Goff, M.D.

Received September 2, 2005; revised May 26, 2006; accepted June 13, 2006. From the Massachusetts General Hospital Schizophrenia Program, the Division of Infectious Diseases and Partners AIDS Research Center; the Division of Psychiatry and Medicine, and Harvard Medical School, Boston, MA. Send correspondence and reprint requests to Oliver Freudenreich, M.D., MGH Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St., Second Floor, Boston, MA 02114. e-mail: ofreudenreich{at}partners.org
© 2007 The Academy of Psychosomatic Medicine

Hepatitis C virus (HCV) infection occurs in up to 20% of patients with chronic mental illnesses. To determine the prevalence of hepatitis C in a diagnostically well-defined sample, the authors screened all schizophrenia outpatients in a clozapine clinic (N=98) for HCV antibodies. Eight patients were positive for hepatitis C antibodies (antibody-positive prevalence: 8.2%); of those, 50% had detectable viral loads (viremia-positive prevalence: 4.1%). Screening for HCV infection should be considered for outpatients with schizophrenia. However, clinical experience treating HCV in schizophrenia patients is limited; in this cohort, 2 years after screening, no patient had received interferon/ribavirin treatment.







Get information about faster international access.

Privacy Policy

Copyright © 2007 Academy of Psychosomatic Medicine. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. Academy of Psychosomatic Medicine
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org